Yang Jianxin, CEO of Cornerstone Pharmaceuticals, believes t...

Moomoo AI Oct 23, 2023 21:27

Yang Jianxin, CEO of Cornerstone Pharmaceuticals, believes that Jejaine's clinical value in first-line gastric cancer has been recognized. Due to the poor prognosis of advanced gastric cancer patients, Professor Shen Lin of Peking University Cancer Hospital pointed out that Jejaine combined with chemotherapy has significant significance in prolonging the survival of such patients and may be their new treatment option.

Cornerstone Pharmaceuticals (02616) announced the results of the GEMSTONE-303 study: Jejaine combined with chemotherapy significantly improved PFS and OS.

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

2767 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4554Followers

0Following

9952Visitors